Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 UCAR-T in B-cell Acute Lymphoblastic Leukemia
NCT04166838Phase 1Unknown
- Sponsor
- Shanghai Longyao Biotechnology Co., Ltd.
- Start
- Nov 2019
- Primary completion
- Nov 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of UCART19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shanghai Longyao Biotechnology Co., Ltd. Primary endpoints: Adverse events at 24 weeks and Graft-versus-Host Disease at 42 days. Status: unknown.
02
Drugs
UCART19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04166838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166838.